On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #255 entitled, “Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia A with and without Inhibitors”.
Emicizumab is a novel recombinant, humanized, bispecific monoclonal antibody that substitutes for part of the function of activated factor VIII (FVIIIa) by bridging activated factor IX(FIXa) and factor X(FX). It is licensed for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children of all ages, newborn and older, with hemophilia A with and without factor VIII inhibitors.
MASAC’s recommendation covers topics including clinical management guidance, who should be considered for treatment with emicizumab, initiation of emicizumab for people with hemophilia A (PwHA) with and without inhibitors, important topics for patient education, acute bleed management for PwHA with and without inhibitors and recommended laboratory assays.
The Medical Advisory Board of the WFH supports MASAC’s, “Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia A with and without Inhibitors” published on December 6, 2018.
Click here to read the recommendation published by MASAC.